Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C23H14ClF3N6O |
|||
Molecular Weight | 482.85 | CAS No. | 1362850-20-1 | |
Solubility (25°C)* | In vitro | DMSO | 97 mg/mL (200.89 mM) | |
Ethanol | 97 mg/mL (200.89 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Seletalisib (UCB-5857) is a novel small-molecule inhibitor of PI3Kδ with an IC50 value of 12 nM and shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (between 24- and 303-fold). | ||||
---|---|---|---|---|---|
Targets |
|
||||
In vitro | Seletalisib is a potent, ATP-competitive, and selective PI3Kδ inhibitor able to block protein kinase B (AKT) phosphorylation following activation of the B-cell receptor in a B-cell line. Moreover, seletalisib inhibited N-formyl peptide-stimulated but not phorbol myristate acetate–stimulated superoxide release from human neutrophils, consistent with a PI3Kδ-specific activity. Findings from cellular assays of adaptive immunity demonstrated that seletalisib blocks human T-cell production of several cytokines from activated T-cells. Additionally, seletalisib inhibited B-cell proliferation and cytokine release. In human whole blood assays, seletalisib inhibited CD69 expression upon B-cell activation and anti-IgE-mediated basophil degranulation. From 239 kinases screened, seletalisib at a concentration of 10 μM showed no inhibitory activity greater than 47% (MAP4K4) against non-PI3K kinase enzymes. Against nonkinase enzymes, seletalisib showed weak activities against phosphodiesterase (PDE)3A, PDE2A1, and PDE4D2, with inhibition varying between 32 and 74% at 10 μM. When screened at a concentration of 10 μM against 55 receptors and ion channels, the highest inhibitory activity of seletalisib observed was 20%. One receptor, neuropeptide Y receptor (Y1) showed 54% activation. In vitro receptor binding and enzyme assays across a broad range of target classes showed that seletalisib is selective for PI3Kδ. Seletalisib potently inhibited the phosphorylation of AKT following anti-IgM stimulation of the BCR on Ramos cells with an IC50 of 15 nM[1]. When profiled in a wide range of primary cell assay systems, including fibroblasts, epithelial, endothelial and vascular smooth muscle cells, seletalisib showed significant activity only in those systems containing lymphocytes, demonstrating its functional selectivity towards PI3Kδ-expressing cells[2]. |
||||
In vivo | Seletalisib shows dose-dependent inhibition in an in vivo rat model of anti-CD3-antibody-induced interleukin 2 release. Analysis of the relationship between inhibition of IL-2 release and seletalisib blood concentration, using combined data across experiments, demonstrated that seletalisib has potent in vivo effects with an estimated IC50 value of <10 nM[1]. In first-in-man studies, mean seletalisib plasma concentration-time profiles increased with increasing dose after single and multiple dosing, with no major deviations from dose proportionality. There was no unexpected accumulation or loss of exposure after multiple dosing (time-independent pharmacokinetic (PK) profile) and apparent t1/2 values (approx. 20h) were supportive of once-daily dosing[2]. |
Kinase Assay: |
|
---|---|
Cell Assay: |
|
Animal Study: |
|
|
The phosphoinositide-3-kinase (PI3K)-delta inhibitor seletalisib impairs monocyte-derived dendritic cells maturation, APC function, and promotes their migration to CCR7 and CXCR4 ligands [ J Leukoc Biol, 2022, 10.1002/JLB.1A0821-413RR] | PubMed: 35199885 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.